Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies
- 1Hematology and Medical Oncology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA
Abstract
The simultaneous presence of thyroid carcinoma with other non-thyroid malignancies poses unique treatment dilemmas. Optimal treatment strategies for patients with simultaneous papillary thyroid carcinoma and breast cancer have not been clearly identified. There is increasing attention focused on targeting molecular markers common to both tumors, such as trophoblast cell surface antigen 2 (Trop-2). Herein, we report an 86-year-old female with hormone receptor-positive, HER2-low metastatic breast cancer and an RAI-refractory, BRAF V600E-mutated, metastatic papillary thyroid carcinoma with Trop-2 expression. Following four cycles of sacituzumab govitecan for the breast cancer, she was re-staged. Radiographic studies revealed a partial response to the regimen for the pulmonary metastases along with improvement in thyroglobulin levels and marked reduction of breast tumor markers. This case highlights the possibility of cross-tumor efficacy of Trop-2 targeted agents, thus providing the rationale that sacituzumab govitecan should be explored in RAI-refractory differentiated thyroid cancer.
Related
- Emerging trophoblast cell-surface antigen 2-targeting antibody-drug conjugates in gynecological cancers
- Spatial Transcriptomic Profiling of the Human Placenta in Congenital Cytomegalovirus Infection: A Broad Antiviral Response with Concurrent Suppression of Trophoblast and Vascular Programs.
- Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells
- Model-based integration of chimeric antigen receptor T-cell kinetics and tumor features to predict therapeutic outcomes in patients with B-cell malignancies
- Cholesterol requirement of hepatitis B surface antigen (HBsAg) secretion
BibTeX
@article{berkowitz2026antitrophoblast,
title = {{Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies}},
author = {Maurice J Berkowitz and Karo K Arzoo},
journal = {Cureus},
year = {2026},
month = oct,
doi = {10.7759/cureus.117545},
url = {https://doi.org/10.7759/cureus.117545},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Anti-trophoblast Cell-Surface Antigen 2 (TROP2)-Based Therapy for Concurrent Breast and Thyroid Malignancies
AU - Maurice J Berkowitz
AU - Karo K Arzoo
PY - 2026
DA - 2026/10/06
JO - Cureus
DO - 10.7759/cureus.117545
UR - https://doi.org/10.7759/cureus.117545
AB - The simultaneous presence of thyroid carcinoma with other non-thyroid malignancies poses unique treatment dilemmas. Optimal treatment strategies for patients with simultaneous papillary thyroid carcinoma and breast cancer have not been clearly identified. There is increasing attention focused on targeting molecular markers common to both tumors, such as trophoblast cell surface antigen 2 (Trop-2). Herein, we report an 86-year-old female with hormone receptor-positive, HER2-low metastatic breast cancer and an RAI-refractory, BRAF V600E-mutated, metastatic papillary thyroid carcinoma with Trop-2 expression. Following four cycles of sacituzumab govitecan for the breast cancer, she was re-staged. Radiographic studies revealed a partial response to the regimen for the pulmonary metastases along with improvement in thyroglobulin levels and marked reduction of breast tumor markers. This case highlights the possibility of cross-tumor efficacy of Trop-2 targeted agents, thus providing the rationale that sacituzumab govitecan should be explored in RAI-refractory differentiated thyroid cancer.
SN - 2168-8184
ER -